Inhibitors of HSP90 and other chaperones for the treatment of cancer

Bibliography

• HARTL FU: Molecular chaperones in cellular protein folding. Nature (1996) 381(6583):571–580.
   PubMed Web of Science ®Google Scholar
• JOLLY C, MORIMOTO RI: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. Nati Cancer Inst. (2000) 92(19):1564–1572.
   PubMedGoogle Scholar
• MALONEY A, WORKMAN P: HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. (2002) 2(1):3–24.
   PubMed Web of Science ®Google Scholar
• WORKMAN P: Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets (2003) 3:297–300.
   PubMed Web of Science ®Google Scholar
• ••Overview and introduction to a series ofrecent articles, published within a special issue, that provide an up to date insight into the biology of HSP90 and the therapeutic potential of inhibitors of this molecular chaperone.
   Google Scholar
• WORKMAN P: Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. (2004) 10(2):47–51.
   PubMed Web of Science ®Google Scholar
• •Commentary on [ll].
   Google Scholar
• ISAACS JS, XU W, NECKERS L: Heat- shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3:213–317.
   PubMed Web of Science ®Google Scholar
• PIPER PW: The Hsp90 chaperone as a promising drug target. Curt: Opin. Investig. Drugs (2001) 2:1606–1610.
   Google Scholar
• SUBBARAO AS, SOTI C, CSERIVIELY P: Inhibition of Hsp90: A new strategy for inhibiting protein kinases. Biochlin . Biophys. Acta. (2004) 1697:233–242.
   PubMed Web of Science ®Google Scholar
• CAPLAN AJ, JACKSON S, SMITH D: Hsp 90 reaches new heights: conference in the Hsp90 chaperone machine. EMBO Reports (2003) 4(2):126–130.
   PubMedGoogle Scholar
• SOLIT DB, SCHER HI, ROSEN N: Hsp 90 as a therapeutic target in prostate cancer. Semin. Oncol. (2003) 30:709–716.
   PubMed Web of Science ®Google Scholar
• KAMAL A, THAO L, SENSINTAFFARJ et al.: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 425:407–410.
   PubMed Web of Science ®Google Scholar
• ••A paper that has generated considerableinterest by providing an explanation for the therapeutic selectivity of the Hsp90 inhibitor 17AAG. The results show that the super-chaperone complexes that predominate in cancer but not normal cells exhibit markedly increased sensitivity to the drug compared to the uncomplexed chaperone.
   Google Scholar
• NIMMANAPALLI R., O'BRYAN E, HUANG M et al.: Molecular characterization and sensitivity of STI-571 (imatinib mesylate, gleevec)-resistant, bcr-abl-positive, human acute leukemia cells to SRC kinase inhibitor PD-180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. (2002) 62(20):5761–5769.
   Google Scholar
• GORRE ME, ELLWOOD-YEN K, CHIOSIS G, ROSEN N, SAWYERS CL: BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukaemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood (2004) 100:3041–3044.
   Web of Science ®Google Scholar
• ••This paper illustrates the therapeuticpotential of HSP90 inhibitors in chronic myeloid leukaemia patients resistant to the Bcr-Abl inhibitor imatinib.
   Google Scholar
• DAVIES H, BIGNELL GR, COX C, STEPHENS P, EDKINS S: Mutations of the BRAF gene in human cancer. Nature (2004) 417(6892):949–954.
   Web of Science ®Google Scholar
• PRODROMOU C, ROE M, O'BRIEN R, LADBURYJE, PIPER PW, PEARL L: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell (1997) 90(1):65–75.
   PubMed Web of Science ®Google Scholar
• STEBBINS CE, RUSSO AA, SCHNEIDER C, ROSEN N, HARTL FU, PAVLETICH NP: Crystal structure of an Hsp9 0-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 89(2):239–250.
   PubMed Web of Science ®Google Scholar
• PEARL LH, PRODROMOU C: Structure and in vivo function of Hsp90. Carr: Opin. Strad. Biol. (2000) 10:46–51.
   Google Scholar
• PEARL LH, PRODROMOU C: Structure, function and mechanism of the Hsp90 molecular chaperone. Adv. Protein Chem. (2002) 59:157–186.
   Google Scholar
• DUTTA R, INOUYE M: GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. (2000) 25(1):24–28.
   PubMed Web of Science ®Google Scholar
• BANJERI U, JUDSON I, WORKMAN P: The clinical applications of heat shock protein inhibitors in cancer - present and future. Current Cancer Drug Targets (2003) 3:385–390.
   PubMed Web of Science ®Google Scholar
• SAUSVILLE EA, TOMASZEWSKI JE, IVY P: Clinical development of 17-allylamino,17-demethoxygeldanamycin. Current Cancer Drug Targets (2003) 3:377–383.
   PubMed Web of Science ®Google Scholar
• ••Timely review of the development of17AAG.
   Google Scholar
• CLARK JI: Therapeutic applications of heatshock proteins and molecular chaperones. Expert Opin. Ther. Patents (2001) 11(7):1353–1160.
   Web of Science ®Google Scholar
• DEBOER C, MEULMAN PA, WNUK RJ, PETERSON DH: j Antibiot. (1970) 33:442–447.
   Google Scholar
• CHIOSIS G, HUEZO H, ROSEN N, MIMNAUGH E, WHITESELL L, NECKERS L: 17AAG: low target binding affinity and potent cell activity - finding an explanation. Ma Cancer The]: (2003) 2:123–129.
   PubMed Web of Science ®Google Scholar
• •This work illustrates the importance of the cellular accumulation of 17AAG and together with [11] provides an explanation for the greater potency of 17AAG than would be predicted from its affinity for HSP90.
   Google Scholar
• BANERJI U, O'DONNELL A, SCURR M et al.: Phase I trial of the heat shock protein 90 (HSP9 0) inhibitor 17-allylamino 17-demethoxygeldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc. Am. Soc. Clin. Oncol (2001) 20:82a.
   Google Scholar
• ERLICHMAN C, TOFT D, REID J et al:A Phase I trial of 17-allylamino-geldanamycin in patients with advanced cancer. Proc. Am. Assoc. Cancer Res. (2001) 42:833.
   Google Scholar
• MUNSTER PN, TONG L, SCHWARTZ L et al.: Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in patients (Pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol (2001) 20:83a.
   Google Scholar
• WILSON RH, TAKIMOTO CH, ADNEW EB et al.: Phase I pharmacokinetic study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2001) 20:82a.
   Google Scholar
• EGORIN MJ, LAGATTUTA TF, HAMBURGER DR et al: Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother. Pharmacol (2002) 49:7–19.
   PubMed Web of Science ®Google Scholar
• KELLAND LR, SHARP SY, ROGERS PM, MYERS TG, WORKMAN P: DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J . Natl. Cancer Inst. (1999) 91:1940–1949.
   PubMed Web of Science ®Google Scholar
• SOGA S, SHIOTSU Y, AKINAGA S, SHARIVIA SV: Development of radicicol analogues. Carr. Cancer Drug Targets (2003) 3:359–369.
   PubMed Web of Science ®Google Scholar
• ••Recent update on the development ofradicicol analogues as HSP90 inhibitors.
   Google Scholar
• IKUINA Y, AMISHIRO N, MIYATA M et al.: Synthesis and antitumor activity of novel 0-carbamoylmethyloxime derivatives of radicicol. Med. Chem. (2003) 46(12):2534–2541.
   Web of Science ®Google Scholar
• KUREBAYASHI J, OTSUKI T, KUROSUMI M, SOGA S, AKINAGA S, SON00 H: A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-la and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Japanese .1. Cancer Res. (2001) 92:1342–1351.
   Google Scholar
• SOGA S, SHARMA SV, SHIOTSU Y et al.: Stereospecific antitumor activity of radicicol oxime derivatives. Cancer Chemother Pharmacol (2001) 48(6):435–445.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO K, GARBACCIO RIVI, STACHEL et al.: Total synthesis as a resource in the discovery of potentially valuable antitumour agents: cycloproparadicicol. Ang. Chem. Int. Ed. (2003) 42(11):1280–1284.
   PubMed Web of Science ®Google Scholar
• JEZ JM, CHEN JH, RASTELLI G, STROUD RM, SANTI DV: Crystal structure and molecular modelling of 17DMAG in complex with human Hsp90. Chem. Biol. (2003) 10:361–368.
   PubMedGoogle Scholar
• •Interesting paper on the co-crystal structure of 17DMAG with HSP90.
   Google Scholar
• ROE SM, PRODROMOU C, O 'BRIEN R, LADBURY JE, PIPER PW, PEARL LH: Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumour antibiotics radicicol and geldanamycin. J. Med. Chem. (1999) 42:260–266.
   PubMed Web of Science ®Google Scholar
• CHIOSIS G, LUCAS B, SHTIL A, HUEZO H, ROSEN N: Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HERZ tyrosine kinase. Bioorg. Med. Chem. (2002) 10(11):3555–3564.
   PubMed Web of Science ®Google Scholar
• CHIOSIS G, LUCAS B, HUEZO H, SOLIT D, BASSO A, ROSEN N: Development of purine-scaffold small molecule inhibitors of Hsp90. Carr: Cancer Drug Targets (2003) 3(5):371–376.
   PubMed Web of Science ®Google Scholar
• ••Recent update on the development ofpurine HSP90 inhibitors.
   Google Scholar
• AHERNE G W, MALONEY A, PRODROMOU C et al.: Assays for HSP90 and inhibitors. In: Methods in Molecular Medicine: Novel Anti-Cancer Drug Protocols. JK Buolamwini, AA Adjei (Eds). Humana Press, Inc., NJ (2003) 85:149–161.
   Google Scholar
• DYMOCK B, BARRIL X, BESWICK M et al.: Adenine-derived inhibitors of the molecular chaperone Hsp90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. (2004) 14(2):325–328.
   PubMed Web of Science ®Google Scholar
• ••This paper and [43] provide a crystallographic explanation for the SAR of purine scaffold HSP90 inhibitors (see also [39]).
   Google Scholar
• LLAUGER-BUFI L, FELTS SJ, HUEZO H, ROSEN N, CHIOSIS G: Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg. Med. Chem. Lett. (2003) 13:3975–3978.
   PubMed Web of Science ®Google Scholar
• WRIGHT L, BARRIL X, DYMOCK BL et al.: Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. (in press).
   Google Scholar
• ••This paper and [41] provide a crystallographic explanation for the SAR of purine scaffold Hsp90 inhibitors (see also [39]).
   Google Scholar
• CHIOSIS G, TIMAUL MN, LUCAS B et al.: A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes HERZ degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. (2001) 8:289–299.
   PubMed Web of Science ®Google Scholar
• CLARKE PA, HOSTEIN I, BANERJI U et al.: Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene (2000) 19(36):4125–4133.
   PubMed Web of Science ®Google Scholar
• HOSTEIN I, ROBERTSON D, DISTEFANO F, WORKMAN P, CLARKE PA: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. (2001) 61(104003–4009.
   Web of Science ®Google Scholar
• SMITH NE HAYES A, JAMES K et al.: Pharmacokinetic and metabolism studies of a novel synthetic series of heat shock protein 90 (Hsp90) inhibitors. Gin. Cancer Res. (2003) 9:239.
   Google Scholar
• AHERNE GW, MALONEY A, SHARP S et al.: Discovery of a novel synthetic inhibitor of the Hsp90 molecular chaperone. Proc. Am. Assoc. Cancer Res. (2003) 44:915.
   Google Scholar
• ROWLANDS MG, NEWBATT YM, PRODROMOU C, PEARL LH, WORKMAN P, AHERNE W: High -throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Analyt. Biochem. (2004) 327:176–183.
   PubMed Web of Science ®Google Scholar
• ••First paper describing high-throughputscreening to identify HSP90 inhibitors, including CCT018159.
   Google Scholar
• MCLAUGHLIN SH, SMITH HW, JACKSON SE: Stimulation of the weak ATPase activity of human Hsp90 by a client protein. J. Ma Biol. (2002) 315(4):787–798.
   Google Scholar
• PANARETOU B, SILIGARDI G, MEYER P et al.: Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone Ahal. Ma Cell (2002) 10(6):1307–1318.
   PubMed Web of Science ®Google Scholar
• ••Identification of the novel co-chaperoneAhal as a potent activator of the ATPase activity of HSP90.
   Google Scholar
• SOLDANO KL, JIVAN A, NICCHITTA CV, GEWIRTH DT: Structure of the N-terminal domain of GRP94: basis for ligand specificity and regulation. J. Biol. Chem. (2003) 278(48):48330–48338.
   PubMed Web of Science ®Google Scholar
• KUMAR R, MUSIYENKO A, BARIK S: The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin. Malaria (2003) 2(1):30.
   PubMedGoogle Scholar
• ROE MS, ALI MARUF MU, MEYER P et al.: The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). CO (2004) 116(1):87–98.
   Google Scholar
• •Co-crystal structure of the kinase-specific co-chaperone p50/cdc37 with HSP90.
   Google Scholar
• QUEITSCH C, SANGSTER TA, LINDQUIST S: Hsp90 as a capacitor of phenotypic variation. Nature (2002) 417:618–624.
   PubMed Web of Science ®Google Scholar
• ••Ground breaking paper demonstrating thatHSP90 has the ability to buffer the effects of mutations, which are then expressed when HSP90 is inhibited. This has implications for developmental evolution and potentially for therapy.
   Google Scholar